120 related articles for article (PubMed ID: 10541970)
41. [Inhibitory effects of TNP-470 in combination with 5-fluorouracil on growth of human colon cancer].
Fan YF; Huang ZH; Nie J
Ai Zheng; 2002 Dec; 21(12):1319-23. PubMed ID: 12520739
[TBL] [Abstract][Full Text] [Related]
42. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
Juweid ME; Zhang CH; Blumenthal RD; Hajjar G; Sharkey RM; Goldenberg DM
J Nucl Med; 1999 Oct; 40(10):1609-16. PubMed ID: 10520699
[TBL] [Abstract][Full Text] [Related]
43. Anti-angiogenic therapy and radioimmunotherapy in colon cancer xenografts.
Kinuya S; Kawashima A; Yokoyama K; Kudo M; Kasahara Y; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
Eur J Nucl Med; 2001 Sep; 28(9):1306-12. PubMed ID: 11585288
[TBL] [Abstract][Full Text] [Related]
44. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
[TBL] [Abstract][Full Text] [Related]
45. Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy.
Kinuya S; Yokoyama K; Koshida K; Mori H; Shiba K; Watanabe N; Shuke N; Bai J; Michigishi T; Tonami N
Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):981-5. PubMed ID: 14991242
[TBL] [Abstract][Full Text] [Related]
46. Improved experimental radioimmunotherapy of colon xenografts by combining 131I-CC49 and interferon-gamma.
Greiner JW; Guadagni F; Roselli M; Ullmann CD; Nieroda C; Schlom J
Dis Colon Rectum; 1994 Feb; 37(2 Suppl):S100-5. PubMed ID: 8313780
[TBL] [Abstract][Full Text] [Related]
47. Importance of timing of radioimmunotherapy after granulocyte colony-stimulating factor administration for peripheral blood stem cell harvest.
Juweid ME; Blumenthal RD; Lew W; Hajjar G; Rubin AD; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3337s-3342s. PubMed ID: 10541383
[TBL] [Abstract][Full Text] [Related]
48. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
Behr TM; Salib AL; Liersch T; Béhé M; Angerstein C; Blumenthal RD; Fayyazi A; Sharkey RM; Ringe B; Becker H; Wörmann B; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3232s-3242s. PubMed ID: 10541369
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies.
Behr TM; Béhé M; Löhr M; Sgouros G; Angerstein C; Wehrmann E; Nebendahl K; Becker W
Eur J Nucl Med; 2000 Jul; 27(7):753-65. PubMed ID: 10952487
[TBL] [Abstract][Full Text] [Related]
50. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
51. Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma.
Ishikawa T; Tanaka Y; Ishitsuka H; Ohkawa T
Jpn J Cancer Res; 1989 Jun; 80(6):583-91. PubMed ID: 2527217
[TBL] [Abstract][Full Text] [Related]
52. Continuous infusion chemotherapy as a radiation-enhancing agent for yttrium-90-radiolabeled monoclonal antibody therapy of a human tumor xenograft.
Remmenga SW; Colcher D; Gansow O; Pippen CG; Raubitschek A
Gynecol Oncol; 1994 Oct; 55(1):115-22. PubMed ID: 7959251
[TBL] [Abstract][Full Text] [Related]
53. Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts.
Kinuya S; Kawashima A; Yokoyama K; Koshida K; Konishi S; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
J Nucl Med; 2002 Aug; 43(8):1084-9. PubMed ID: 12163635
[TBL] [Abstract][Full Text] [Related]
54. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
[TBL] [Abstract][Full Text] [Related]
55. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
56. Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel.
Ning S; Trisler K; Brown DM; Yu NY; Kanekal S; Lundsten MJ; Knox SJ
Radiother Oncol; 1996 May; 39(2):179-89. PubMed ID: 8735485
[TBL] [Abstract][Full Text] [Related]
57. The modulation by L-leucovorin of 5-fluorouracil antitumor activity on human colon carcinoma cells in vitro and in vivo.
Kase S; Kubota T; Watanabe M; Takahara T; Takeuchi T; Yamaguchi H; Furukawa T; Teramoto T; Kodaira S; Ishibiki K
Surg Today; 1993; 23(7):615-20. PubMed ID: 8369613
[TBL] [Abstract][Full Text] [Related]
58. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
[TBL] [Abstract][Full Text] [Related]
59. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin.
Domingo RJ; Reilly RM
Nucl Med Commun; 2000 Jan; 21(1):89-96. PubMed ID: 10717908
[TBL] [Abstract][Full Text] [Related]
60. Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacy.
Dearling JL; Qureshi U; Begent RH; Pedley RB
Clin Cancer Res; 2007 Mar; 13(6):1903-10. PubMed ID: 17363547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
